2024-05-09 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress |
2024-05-03 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
2024-04-05 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
2024-03-28 08:30 | UU:ATRA | | News Release200 | Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress |
2024-02-29 09:05 | UU:ATRA | | News Release200 | Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy |
2024-02-28 16:30 | UU:ATRA | | News Release200 | Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference |
2024-02-14 09:00 | UU:ATRA | | News Release200 | Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis |
2024-01-31 18:30 | UU:ATRA | | News Release200 | Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel ‚ ® Data in The Lancet Oncology |
2024-01-08 09:00 | UU:ATRA | | News Release200 | Atara Biotherapeutics Announces $15 Million Registered Direct Offering |
2024-01-08 08:00 | UU:ATRA | | News Release200 | Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference |
2024-01-04 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference |
2023-12-20 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel ‚ ® Partnership with Pierre Fabre Laboratories |
2023-12-11 12:00 | UU:ATRA | | News Release200 | Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting |
2023-12-01 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
2023-11-29 18:05 | UU:ATRA | | News Release200 | Atara Biotherapeutics To Present Positive New Tab-cel ‚ ® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023 |
2023-11-22 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference |
2023-11-10 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics To Participate at the Stifel Healthcare Conference |
2023-11-08 17:35 | UU:ATRA | | News Release200 | Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis |
2023-11-01 08:30 | UU:ATRA | | News Release200 | Atara Biotherapeutics Announces Expanded Global Tab-cel ‚ ® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results |
2023-10-06 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
2023-09-19 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics Announces Plans to Submit Tab-cel ‚ ® BLA in Q2 2024 Following FDA Agreement on Comparability |
2023-09-01 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
2023-08-31 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference |
2023-08-08 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress |
2023-08-04 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
2023-07-31 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference |
2023-07-07 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
2023-06-07 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference |
2023-06-05 09:00 | UU:ATRA | | News Release200 | Atara Biotherapeutics Presents Updated Tab-cel ‚ ® Clinical Effectiveness Data at ASCO 2023 |
2023-06-02 16:01 | UU:ATRA | | News Release200 | Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |